Goldman Sachs’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $620K | Sell |
155,008
-78,553
| -34% | -$314K | ﹤0.01% | 4147 |
|
|
2025
Q1 | $213K | Sell |
233,561
-19,161
| -8% | -$17.4K | ﹤0.01% | 4657 |
|
|
2024
Q4 | $700K | Sell |
252,722
-194,595
| -44% | -$539K | ﹤0.01% | 4121 |
|
|
2024
Q3 | $2.34M | Buy |
447,317
+85,449
| +24% | +$447K | ﹤0.01% | 3259 |
|
|
2024
Q2 | $1.61M | Sell |
361,868
-48,055
| -12% | -$214K | ﹤0.01% | 3311 |
|
|
2024
Q1 | $3.14M | Buy |
409,923
+46,551
| +13% | +$357K | ﹤0.01% | 2914 |
|
|
2023
Q4 | $1.55M | Buy |
363,372
+309,484
| +574% | +$1.32M | ﹤0.01% | 3374 |
|
|
2023
Q3 | $226K | Buy |
53,888
+19,499
| +57% | +$81.9K | ﹤0.01% | 4212 |
|
|
2023
Q2 | $192K | Buy |
+34,389
| New | +$192K | ﹤0.01% | 4410 |
|
|
2023
Q1 | – | Sell |
-11,924
| Closed | -$12.5K | – | 5178 |
|
|
2022
Q4 | $12.5K | Buy |
+11,924
| New | +$12.5K | ﹤0.01% | 4926 |
|
|
2022
Q3 | – | Sell |
-12,505
| Closed | -$60K | – | 5568 |
|
|
2022
Q2 | $60K | Sell |
12,505
-750
| -6% | -$3.6K | ﹤0.01% | 5243 |
|
|
2022
Q1 | $54K | Buy |
13,255
+16
| +0.1% | +$65 | ﹤0.01% | 5454 |
|
|
2021
Q4 | $90K | Sell |
13,239
-3,326
| -20% | -$22.6K | ﹤0.01% | 5250 |
|
|
2021
Q3 | $192K | Sell |
16,565
-2,745
| -14% | -$31.8K | ﹤0.01% | 4878 |
|
|
2021
Q2 | $329K | Sell |
19,310
-4,480
| -19% | -$76.3K | ﹤0.01% | 4655 |
|
|
2021
Q1 | $471K | Buy |
23,790
+2,951
| +14% | +$58.4K | ﹤0.01% | 4404 |
|
|
2020
Q4 | $430K | Buy |
20,839
+7,159
| +52% | +$148K | ﹤0.01% | 3904 |
|
|
2020
Q3 | $360K | Buy |
+13,680
| New | +$360K | ﹤0.01% | 3810 |
|